JHEP Reports

Papers
(The H4-Index of JHEP Reports is 38. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Changing epidemiology of hepatocellular carcinoma in the Mediterranean area: A challenge for surveillance?213
The weight of choices: Prioritizing lifestyle over GLP-1 receptor agonist therapy in managing MASLD152
Identifying emergency presentations of chronic liver disease using routinely collected administrative hospital data123
External validation of the IAIHG autoimmune hepatitis response criteria in a multicentric real-world cohort78
Statistical precision of p values: a note on “Liver fibrosis progression analyzed with AI predicts renal decline”77
Combined inhibition of bile salt synthesis and intestinal uptake reduces cholestatic liver damage and colonic bile salts in mice73
Reply to: “Dynamic imaging of macrophages in MASLD: A major interest in insulin resistance and outside the liver”71
Copyright and information69
Erratum to “Opinion paper on the diagnosis and treatment of progressive familial intrahepatic cholestasis” [JHEP Reports 6 (2024) 100949]68
MELD 3.i: A Bayesian framework for updating the model for end-stage liver disease score65
Induction of phospholipase A2 group 4C by HCV infection regulates lipid droplet formation65
AFP score and metroticket 2.0 perform similarly and could be used in a “within-ALL” clinical decision tool61
Development and validation of circulating protein signatures as diagnostic biomarkers for biliary tract cancer57
Copyright and information57
JMJD2D stabilises and cooperates with HBx protein to promote HBV transcription and replication54
Increased carbohydrate deficient transferrin: Whisky or candy?53
What to do about hepatocellular carcinoma: Recommendations for health authorities from the International Liver Cancer Association52
Mapping the hemodynamic effects of terlipressin in patients with hepatorenal syndrome using advanced magnetic resonance imaging50
Heterogeneity in intrahepatic macrophage populations and druggable target expression in patients with steatotic liver disease-related fibrosis50
Protective role of physical activity against HCC risk in type 2 diabetes: Evidence and public health perspectives50
Inevitability of disease recurrence after liver transplantation for NAFLD cirrhosis48
Emerging roles of circular RNAs in liver cancer47
Hepatitis C virus replication requires integrity of mitochondria-associated ER membranes45
Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-negative chronic hepatitis B: A multicentre cohort st45
Time for a globally unified chronic HBV terminology?44
Liver stiffness measurement predicts clinical outcomes in autoimmune hepatitis44
HCV microelimination in harm reduction centres has benefits beyond HCV cure but is hampered by high reinfection rates44
Comparative effectiveness of antidiabetic therapies on hepatic decompensation in patients with type 2 diabetes: A target trial emulation42
A small animal model of chronic hepatitis E infection using immunocompromised rats42
Predicting liver ablation volumes with real-time MRI thermometry41
Shunt magnitude is a key determinant of overt hepatic encephalopathy in patients undergoing TIPS40
Editorial Board page39
Understanding virologic heterogeneity in chronic hepatitis B treatment39
Human umbilical cord mesenchymal stem cell-derived exosomes ameliorate liver steatosis by promoting fatty acid oxidation and reducing fatty acid synthesis39
Reply to: “Changing epidemiology of hepatocellular carcinoma in the Mediterranean area: A challenge for surveillance?”39
Epigenetics of alcohol-related liver diseases39
Editorial Board page38
PLOD1 promotes the malignancy of hepatocellular carcinoma by facilitating the NF-κB/IL-6/STAT3-dependent TCA cycle38
0.055327892303467